REVIEW article
Front. Oncol.
Sec. Breast Cancer
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1607960
This article is part of the Research TopicLiquid Biopsy and Circulating Tumor DNA Assays in the Management of Breast CancerView all 3 articles
Liquid biopsy in TNBC: significance in diagnostics, prediction, and treatment monitoring
Provisionally accepted
- 1School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China
- 2Department of Clinical Laboratory, Second Hospital of Tianjin Medical University, Tianjin, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Breast cancer is the most common malignant tumor and the leading cause of mortality among women worldwide. Triple-negative breast cancer (TNBC) is recognized as t the most aggressive form of breast cancer, with a poor prognosis and a high mortality rate within two years. The role of tumor markers in facilitating the early diagnosis, treatment, and monitoring of therapeutic efficacy and prognosis in TNBC is well-established. Currently, tissue biopsy remains the standard clinical method for determining tumor histology and staging. However, the invasive nature of tissue biopsy often leads to poor patient compliance, especially when repeated biopsies are required. In contrast, liquid biopsy offers several advantages: it is non-invasive, sample collection is straightforward, it can reflect the overall tumor burden and heterogeneity, and it allows for real-time monitoring. The markers primarily encompass circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), microRNAs (miRNAs), long ncRNA (lncRNAs), exosome, and so forth. The present review aims to provide a comprehensive overview of the recent advancements and potential clinical applications of liquid biopsy technology in the context of TNBC.
Keywords: TNBC, diagnostics, liquid biopsy, CTCs, CtDNA, miRNAs, lncRNAs
Received: 08 Apr 2025; Accepted: 17 Jul 2025.
Copyright: © 2025 Sheng and Zong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xiaolong Zong, Department of Clinical Laboratory, Second Hospital of Tianjin Medical University, Tianjin, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.